Trial-by-gene · MET exon 14
Active trials enrolling MET exon 14 skipping NSCLC
Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.
MET exon 14 skipping NSCLC trials focus on (1) capmatinib / tepotinib post-resistance, (2) next-generation type-Ia MET inhibitors that cover D1228, Y1230, F1200 secondary mutations, (3) ADC combination strategies (telisotuzumab vedotin), and (4) METex14 adjuvant or earlier-line trials.
See the MET exon 14 cheat sheet.
Browse the live listing
Search ClinicalTrials.gov for actively recruiting NSCLC trials with MET exon 14 skipping eligibility.
Open ClinicalTrials.gov listingSource: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.
Representative trial phases and designs
Phase II, post-MET TKI
Next-generation MET inhibitors after capmatinib or tepotinib progression.
Phase I/II, MET ADC
Telisotuzumab vedotin in MET-overexpressing NSCLC including METex14.
Phase III, 1L
Direct comparisons of capmatinib vs tepotinib (rare); 1L combination trials.
Frequently asked questions
- Are METex14 trials open to MET-amplified patients without exon 14 skipping?
- Some are; some require exon 14 skipping specifically. The biology differs and the trials reflect that.